InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-13 | 2026-03-25 | Angotti Vincent J. | Director & CHIEF EXECUTIVE OFFICER | Purchase | 213.3K | $0.59 | $125K | 800.7K | View ↗ | |
| 2026-02-12 | 2026-02-20 | Angotti Vincent J. | Director & CHIEF EXECUTIVE OFFICER | Purchase | 105.4K | $0.81 | $86K | 587.0K | View ↗ | |
| 2026-02-12 | 2026-02-20 | Aslam Shakil | Chief Medical Officer | Purchase | 35.0K | $0.81 | $28K | 83.2K | View ↗ | |
| 2026-02-12 | 2026-02-20 | ASADORIAN RAFFI | Chief Financial Officer | Purchase | 45.0K | $0.81 | $37K | 91.3K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $28K | $0-100.0% | $651K | $0 |
| Research and development | $6.0M-10.2% | $6.7M+21.1% | $5.5M+66.0% | $3.3M |
| Selling, general and administrative | $7.5M-12.4% | $8.5M-28.8% | $12.0M-29.5% | $17.0M |
| Total operating costs and expenses | $13.5M-11.4% | $15.3M-13.0% | $17.5M-30.7% | $25.3M |
| Loss from operations | -$13.5M+11.6% | -$15.3M+9.7% | -$16.9M+33.2% | -$25.3M |
| Interest income and other income, net | $436K-35.8% | $679K-52.0% | $1.4M+286.9% | $366K |
| Gain on sale of future payments | $0-100.0% | $1.2M | $0 | — |
| (Loss) gain on change in fair value of warrant liability | -$1.3M-283.4% | $717K-86.5% | $5.3M | — |
| Non-cash interest expense on liability related to the sale of future payments | $0+100.0% | -$394K | $0 | — |
| Total other income, net | -$879K-139.1% | $2.2M-65.9% | $6.6M-92.2% | $84.4M |
| Net loss from continuing operations | -$14.4M-10.5% | -$13.0M-26.4% | -$10.3M-117.4% | $59.1M |
| Net income from discontinued operations – See Note 3 | $73K | $0+100.0% | -$8.1M+28.7% | -$11.4M |
| Net loss | -$14.3M-9.9% | -$13.0M+29.3% | -$18.4M-138.5% | $47.8M |
| Basic and diluted, continuing operations (in dollars per share) | -$340+32.0% | -$500+30.6% | -$720-109.9% | $7K |
| Basic and diluted, discontinued operations (in dollars per share) | $0 | $0+100.0% | -$570+63.0% | -$2K |
| Basic and diluted loss per share (in dollars per share) | -$340+32.0% | -$500+61.2% | -$1K-122.5% | $6K |
| Shares used in computing net loss per share of common stock, basic and diluted – See Note 10 (in shares) | $42.41B+64.1% | $25.85B+81.2% | $14.26B+93.1% | $7.39B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...
Talphera targets Niyad PMA filing in 2026 and potential approval in 2027 as NEPHRO enrollment surpasses 50%
Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript
Talphera Q1 2026 Earnings Call Transcript